PDCD1 and cancer: Targeting their receptors to stimulate anti-cancer immune responses by applying anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal antibodies and other immune checkpoint inhibitors has been markedly successful in treating numerous malignancies such as melanoma, non-small-cell lung cancer, and ovarian cancer [6].